High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: The GEL-TAMO experience

Annals of Oncology

Volumn 14, Issue 12, 2003, Pages 1768-1775

  Rodriguez J ^a   Caballero, M D ^b   Gutierrez A ^a   Marin J ^c   Lahuerta, J J ^d   Sureda, A ^e   Carreras, E ^f   Leon A ^g   Arranz, R ^h   Fernandez de Sevilla A ⁱ   Zuazu, J ^j   Garcia Larana J ^k   Rifon, J ^l   Varela, R ^m   Gandarillas, M ⁿ   SanMiguel, J ^b   Conde, E ⁿ  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c Hospital Nuestra Senora de Aranzazu   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g HOSPITAL DE JEREZ   (Spain)

^h HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁱ CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k HOSPITAL RAMÓN Y CAJAL   (Spain)

^l UNIVERSITY CLINIC OF NAVARRA   (Spain)

^m HOSPITAL JUAN CANALEJO   (Spain)

ⁿ HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

more..

Author keywords

Autologous transplantation; GEL TAMO; Peripheral T cell lymphoma

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BETA 2 MICROGLOBULIN; BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; MELPHALAN; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL T CELL LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SALVAGE THERAPY; SPAIN; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 9144263865     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg459     Document Type: Article

References (28)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
2. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
3. Armitage JO, Vose JM, Linder J et al. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma. J Clin Oncol 1989; 7: 1783-1790.
4. Coiffier B, Brousse N, Peuchmaur M et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Groupe d'Etude des Lymphomes Agressives (GELA). Ann Oncol 1990; 1: 45-50.
5. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997; 89: 4514-4520.
6. Cheng AL, Chen YC, Wang CH et al. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades - should peripheral T-cell lymphoma be considered separately? J Clin Oncol 1989; 7: 725-731.
7. Kwak LW, Wilson M, Weiss LM et al. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. J Clin Oncol 1991; 9: 1426-1431.
8. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
9. Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de I'Adulte (GELA). Blood 1998; 92: 76-82.
10. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493-1498.
11. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
12. Rodriguez J, Munsell M, Yazji S et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001; 19: 3766-3770.
13. Kewalramani T, Nimer S, Zelenetz A et al. Similar outcomes for chemosensitive (CS) relapsed or primary refractory peripheral T-cell lymphoma (PTCL) and diffuse large B-cell lymphoma (DLBCL) treated with autologous transplantation (ASCT). Blood 2002; 100: 646a.
14. Caballero MD, Perez-Simon JA, Iriondo A et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003; 14: 140-151.
15. Blystad AK, Enblad G, Kvaloy S et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001; 27: 711-716.
16. Rodriguez J, Cabanillas F, McLaughlin P et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol 1992; 3: 711-717.
17. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
18. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
19. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
20. Cox DR. Regression models and life-tables. J R Stat Soc 1972; 34: 187.
21. Shiota M, Nakamura S, Ichinohasama R et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 1995; 86: 1954-1960.
22. Gascoyne RD, Aoun P, Wu D et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93: 3913-3921.
23. Song KW, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003; 120: 978-985.
24. Vose JM, Armitage JO, Bierman PJ et al. Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation. Am J Med 1989; 87: 285-288.
25. Lee HK, Wilder RB, Jones D et al. Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. Leuk Lymphoma 2002; 43: 1769-1775.
26. Mounier N, Simon D, Haioun C et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2002; 20: 1426-1427.
27. Tilly H, Gaulard P, Lepage E et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood 1997; 90: 3727-3734.
28. Falini B, Pileri S, Zinzani PL et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93: 2697-2706.